Immunome Inc. Common Stock (IMNM)

About IMNM

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan r…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

247

Website

immunome.com/

Fundamentals

1-day range

$27.41$28.77

Market cap

$2.61B

P/E (trailing)

—

P/E (forward)

-11.12

EPS (trailing)

$-2.36

Dividend yield

—

Beta

2.55

Avg. volume

1.40M

Forecasts

13 analyst ratings

Immunome Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• IMNM

  Immunome Inc. Common Stock

  $27.57

  ▼ 4.50%
  Market cap $2.61BP/E —
  $8.67$30.06
• SUPN

  Supernus Pharmaceuticals Inc. Common Stock

  $43.76

  ▼ 0.97%
  Market cap $2.67BP/E —
  $42.45$59.68
• TRVI

  Trevi Therapeutics Inc. Common Stock

  $16.78

  ▼ 6.60%
  Market cap $2.54BP/E —
  $6.93$20.22
• RARE

  Ultragenyx Pharmaceutical Inc. Common Stock

  $25.62

  ▼ 2.46%
  Market cap $2.46BP/E —
  $18.29$39.89
• NKTR

  Nektar Therapeutics Common Stock

  $72.57

  ▼ 2.66%
  Market cap $2.38BP/E —
  $27.87$109
• PGEN

  Precigen Inc. Common Stock

  $6.94

  ▼ 3.55%
  Market cap $2.36BP/E —
  $2.99$7.72
• VERA

  Vera Therapeutics Inc. Class A Common Stock

  $34.19

  ▼ 1.18%
  Market cap $2.31BP/E —
  $21.2$56.05

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Truist Securities Maintains Buy on Immunome, Raises Price Target to $38
  benzinga · 8/12/2026

Institutional Ownership

March 31, 2026

Total shares held

113.55M

Total value held

$2.06B

Institutional holders

193